Biomed 101

Drug Profile

Biomed 101

Alternative Names: Biomed101

Latest Information Update: 04 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Chemoprotectants
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 01 Oct 2004 BioMedicines is now called Intarcia Therapeutics
  • 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the adverse events and Cancer pharmacodynamics sections
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top